A phase 1/2 study reported durable activity for a dual-targeting BCMA and CD19 CAR T program in heavily pretreated relapsed or refractory multiple myeloma, including patients with extramedullary disease. The study described deep hematologic and metabolic responses, highlighting a potential pathway for difficult disease biology beyond bone marrow involvement. Because extramedullary myeloma is associated with poor outcomes with standard approaches, the trial’s inclusion of those patients makes the durability signal more clinically meaningful. The update frames the program as showing sustained responses rather than only transient remission. For CAR T developers, the headline takeaway is the feasibility of dual antigen targeting to maintain response pressure in high-risk disease compartments.